Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P, Ferretti G, Di Cosimo S, Giannarelli D, Marolla P, Lopez M, Cortesi E, Antimi M, Terzoli E, Carlini P, Vici P, Botti C, Di Lauro L, Naso G, Nisticò C, Mottolese M, Di Filippo F, Ruggeri EM, Ceribelli A, Cognetti F. Papaldo P, et al. Among authors: naso g. J Clin Oncol. 2006 Jul 1;24(19):3048-55. doi: 10.1200/JCO.2005.02.9488. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769988 Clinical Trial.
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.
Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; “FOLLOW-UP” Study Group. Natoli C, et al. PLoS One. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014. PLoS One. 2014. PMID: 24714591 Free PMC article.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA. Frassoldati A, et al. Among authors: naso g. Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18. Future Oncol. 2020. PMID: 31849236 Review.
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
Orlandi A, Iattoni E, Pizzuti L, Fabbri A, Botticelli A, Di Dio C, Palazzo A, Garufi G, Indellicati G, Alesini D, Carbognin L, Paris I, Vaccaro A, Moscetti L, Fabi A, Magri V, Naso G, Cassano A, Vici P, Giannarelli D, Franceschini G, Marchetti P, Bria E, Tortora G. Orlandi A, et al. Among authors: naso g. J Pers Med. 2020 Dec 18;10(4):291. doi: 10.3390/jpm10040291. J Pers Med. 2020. PMID: 33353132 Free PMC article.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.
Cognetti F, Masetti R, Fabi A, Bianchi G, Santini D, Rognone A, Catania G, Angelucci D, Naso G, Giuliano M, Vassalli L, Vici P, Scognamiglio G, Generali D, Zambelli A, Colleoni M, Tinterri C, Scanzi F, Vigna L, Scavina P, Gamucci T, Marrazzo E, Scinto AF, Berardi R, Fabbri MA, Pinotti G, Franco D, Terribile DA, Tonini G, Cianniello D, Barni S. Cognetti F, et al. Among authors: naso g. NPJ Breast Cancer. 2021 May 5;7(1):47. doi: 10.1038/s41523-021-00246-4. NPJ Breast Cancer. 2021. PMID: 33953182 Free PMC article.
Multigene tests for breast cancer: the physician's perspective.
Cognetti F, Biganzoli L, De Placido S, Del Mastro L, Masetti R, Naso G, Pruneri G, Santini D, Tondini CA, Tinterri C, Tonini G, Barni S. Cognetti F, et al. Among authors: naso g. Oncotarget. 2021 Apr 27;12(9):936-947. doi: 10.18632/oncotarget.27948. eCollection 2021 Apr 27. Oncotarget. 2021. PMID: 33953847 Free PMC article.
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Cerbelli B, Pernazza A, Botticelli A, Fortunato L, Monti M, Sciattella P, Campagna D, Mazzuca F, Mauri M, Naso G, Marchetti P, d'Amati G, Costarelli L. Cerbelli B, et al. Among authors: naso g. Biomed Res Int. 2017;2017:1750925. doi: 10.1155/2017/1750925. Epub 2017 Dec 14. Biomed Res Int. 2017. PMID: 29387716 Free PMC article.
56 results